The Journal of laryngology and otology · 2026
Clinical utility of self-assembling peptide haemostat (PuraBond®) in ENT surgery: a 600-patient observational registry at University Hospitals Birmingham.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zaidi Asiya Kamber, Mohanarajah Naomi Tabitha, Consultants at UHB for Research & Excellence in ENT (CURE ENT Collaborative Group), Ahmed Shahzada K
Аннотация
OBJECTIVES: This study aimed to evaluate the clinical applications, observed haemostatic outcomes of a self-assembling peptide haemostat (PuraBond®) across a range of ENT surgical procedures using a large UK observational registry.
METHODS: A two-cycle observational study of 600 patients at University Hospitals Birmingham NHS Foundation Trust (September 2019-July 2024). Data collected included patient demographics, comorbidities, anticoagulation status, surgical details, intra-operative haemostatic outcomes and post-operative complications.
RESULTS: Intra-operative haemostasis was documented without the need for additional haemostatic intervention in 99.8% of cases (599/600). Immediate haemostasis-related complication rate was 0.2% (1/600). The overall complication rate was 3% per cent, with most complications unrelated to haemostasis or the use of PuraBond. The study limitations include participant heterogeneity, absence of a control group and small subspeciality sample sizes underscoring the need for comparative studies.
CONCLUSION: This registry demonstrates PuraBond's broad applicability in ENT surgery as an adjunct to routine haemostats and provides essential groundwork for designing future comparative trials.
METHODS: A two-cycle observational study of 600 patients at University Hospitals Birmingham NHS Foundation Trust (September 2019-July 2024). Data collected included patient demographics, comorbidities, anticoagulation status, surgical details, intra-operative haemostatic outcomes and post-operative complications.
RESULTS: Intra-operative haemostasis was documented without the need for additional haemostatic intervention in 99.8% of cases (599/600). Immediate haemostasis-related complication rate was 0.2% (1/600). The overall complication rate was 3% per cent, with most complications unrelated to haemostasis or the use of PuraBond. The study limitations include participant heterogeneity, absence of a control group and small subspeciality sample sizes underscoring the need for comparative studies.
CONCLUSION: This registry demonstrates PuraBond's broad applicability in ENT surgery as an adjunct to routine haemostats and provides essential groundwork for designing future comparative trials.